Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World August 22, 2014 Phillip Broadwith	Illumina targets cancer diagnostics Genetic sequencing heavyweight Illumina has partnered with three major pharmaceutical firms in a bid to develop a universal sequencing-based oncology test system.
Chemistry World January 27, 2012 Sarah Houlton	Illumina fends off Roche hostile bid Roche has made a $5.7 billion hostile bid for the genome sequencing company Illumina, after the San Diego, US-based company rejected its initial approach.
The Motley Fool August 18, 2010 Luke Timmerman	Life Technologies Competes for Cheap DNA Sequencing In the race to cheaper gene sequencing.
Chemistry World May 10, 2006 Katharine Sanderson	Leading Lab Suppliers Merge Analytical instrument firm Thermo Electron and chemical manufacturer Fisher Scientific announced a merger, aiming to become the leading provider of laboratory products and services in the health sciences industry.
The Motley Fool April 27, 2011 Brian Orelli	Illuminating the Growth Competition in the DNA sequencing market may be heating up, but 47% growth for Illumina isn't too shabby.
Chemistry World November 21, 2013 Phillip Broadwith	Rapid DNA sequencing cleared for the clinic The approval covers Illumina's MiSeqDx instrument, together with two diagnostic assay kits for cystic fibrosis that run on it, and a kit that allows clinical labs to develop their own diagnostic tests.
Chemistry World January 8, 2013 Andrew Turley	Illumina investment push Gene sequencing company Illumina has struck a $450 million deal to buy privately owned US firm Verinata Health, which specializes in non-invasive tests for early identification of fetal chromosomal abnormalities.
The Motley Fool May 8, 2006 Stephen D. Simpson	Fisher Scientific Reels In a Deal A fair price and impressive market leverage give this merger between Fisher Scientific and Thermo Electron a better-than-average chance. Shareholders, take note.
Chemistry World May 29, 2014 Hepeng Jia	Chinese-made DNA sequencer aims to challenge foreign dominance With an independently developed next-generation DNA sequencer, Chinese scientists are aiming to challenge the dominance of international players in the world's fastest growing genome sequencing market.
The Motley Fool March 30, 2007 Ralph Casale	Another Genetic Sequencer Gobbled Up Roche buys out second-generation sequencer 454 Life Sciences. Investors, take note.
The Motley Fool February 7, 2008 Brian Orelli	A Lab Match Made in Heaven The case of Thermo Electron and Fisher Scientific shows why mergers work.
The Motley Fool February 8, 2010 Brian Orelli	An Earnings Surprise of an Unusual Kind Illumina beats management's own preliminary revenue announcement.
The Motley Fool October 28, 2009 Brian Orelli	Ugly, but Still Built for Growth It continues to be a tale of two business segments for Illumina, with sales from the consumables used in its sequencing machines more than doubling, while its array business remains down considerably.
Chemistry World January 8, 2014 Phillip Broadwith	Thermo Fisher to sell three analytical divisions to GE Healthcare GE will take over Thermo's cell culture supplies, gene modulation and magnetic beads businesses, which are expected to generate combined sales in the region of $250 million for 2013.
Bio-IT World October 2005 Dennis A. Gilbert	The DNA Sequencing Race: From Sprint to Marathon To create faster, cheaper, and better solutions for DNA analysis, we must remain committed to improving both current and new sequencing technologies. Research that just a short while ago might have been considered too complex, too expensive, or just inconceivable is now well within our grasp.
The Motley Fool November 17, 2006 Jack Uldrich	Neanderthal DNA Enlightens Investors Investors, the superb performance of 454's gene sequencing equipment on such a difficult and important project bodes well for its future prospects.
The Motley Fool August 19, 2011 Alexander Crawford	DNA Sequencing: The Next High-Growth Market in Biotech? We compiled a list of companies with a hand in the DNA sequencing market. Should you add these companies to your watch list?
The Motley Fool August 12, 2009 Brian Orelli	The Next Big Thing Is Not Right in Front of You Perhaps the fastest evolving technology right now is found in DNA sequencing.
The Motley Fool January 14, 2010 Brian Orelli	$1,000 Genomes, Here We Come Illumina jumps on news of its $10,000 genome.
The Motley Fool October 26, 2007 Brian Orelli	This Just In: Mergers Do Indeed Lower Costs As the anniversary integration between Thermo Electron and Fisher Scientific approaches next week, Thermo Fisher Scientific announced third-quarter results that demonstrated how the integration is having a nice effect on the bottom line.
Bio-IT World Jul/Aug 2006 Kate McDonald	The Next Generation in Sequencing Is SOLiD Applied Biosystems has completed the acquisition of genetic analysis company Agencourt Personal Genomics for $120 million, and hopes to bring the company's novel next-generation sequencing technology to market next year.
Chemistry World July 8, 2015 Phillip Broadwith	Thermo Fisher to buy Alfa Aesar chemical supplies The acquisition complements its existing Fisher Scientific chemicals supply segment, and will be integrated with its laboratory products and services portfolio.
The Motley Fool October 26, 2011 Tim Beyers	Thermo Fisher Scientific Shares Plunged: What You Need to Know Shares of Thermo Fisher Scientific fell more than 10% in early trading and closed off almost that much after lowering full-year earnings and revenue guidance.
Chemistry World July 21, 2011 James Mitchell Crow	Sequencing Chip Decodes DNA Proton by Proton Technology that can directly detect the chemical reaction as a single nucleotide adds to the end of a growing strand of DNA is about to slash the cost of genome sequencing, its inventors say.
The Motley Fool January 3, 2012 Alex Planes	Another Entry in the Genome Patent Rumble There's a whole lot of lawsuits going on.
Bio-IT World April 2007	News Briefs Molecular Medicine's "Best of Show"... Dissolving Assets... Combined Forces...
The Motley Fool August 16, 2007 Brian Orelli	More Drugmaker Growth Without the FDA All that high-tech lab equipment has to come from somewhere. Here's how investors can benefit from it, too.
Chemistry World September 26, 2014 Rebecca Trager	Merck KGaA to buy Sigma--Aldrich German chemicals conglomerate Merck KGaA has agreed to buy US specialty chemicals company Sigma -- Aldrich for $17 billion
BusinessWeek November 6, 2006 Gene G. Marcial	Solexa's Progress Is In The Genes New technology makes Solexa a leading contender in the next-generation sequencing race.
The Motley Fool May 28, 2010 Brian Orelli	Is It Time to Make Money Investing in Genetic Testing? Easier said than done.
IEEE Spectrum March 2013 Eliza Strickland	The Gene Machine and Me Ion Torrent's chip-based genome sequencer is cheap, fast, and poised to revolutionize medicine
The Motley Fool September 25, 2006 Jack Uldrich	DNA Sequencing Sprouts Small Roots DNA sequencing of the poplar tree may lead to cheaper, more plentiful biofuels. Investors, take note.
The Motley Fool February 6, 2008 Brian Orelli	Insatiable Illumina Revenue is way up at Illumina, but can the company keep it going looking forward?
The Motley Fool February 4, 2009 Brian Orelli	43% Growth! Yee-Haw! Illumina rocks another quarter.
BusinessWeek April 28, 2011 Ashlee Vance	Pacific Biosciences' $600 Million Decoder Ring Pacific Biosciences' technology may finally fulfill the dream of gene sequencing.
BusinessWeek October 23, 2008 John Carey	Reading the Entire Genetic Code Pioneers such as 23andMe and Navigenics use snips of genes to make medical predictions. Now new tools from more start-ups are on the horizon.
The Motley Fool July 24, 2008 Brian Orelli	Illumina Polishes Its Biochips There's very little to complain about in Illumina's earnings report. In this market, you'll see few investors grumbling about double-digit growth.
CFO January 10, 2007 Roy Harris	The Year of Living Strategically While private-equity bids got lots of attention, some public-company mergers aimed to remake their industries in 2006.
CIO July 27, 2012 Kim S. Nash	How Thermo Fisher Mines Customer Feedback to Improve Service Thermo Fisher Scientific overhauled its customer feedback system to allow it to be more responsive to current customers and to take advantage of emerging markets
The Motley Fool September 28, 2006 Jack Uldrich	Is CuraGen Hiding a Genomic Gem? A majority ownership stake in 454 Life Sciences could pay hefty dividends.
Bio-IT World February 2006 Kevin Davies	Solexa Readies 1G Genetic Analyzer Solexa, one of the firms vying to crack the $1,000 genome threshold, has officially launched its first commercial genome sequencing instrument.
The Motley Fool June 10, 2010 Denise Gellene	Syndax's Breast Cancer Drug Advances, and More San Diego Life-Sciences News The pace of life-sciences news slowed in the past week, but we know from experience that the lull is temporary.
The Motley Fool April 22, 2009 Brian Orelli	Illuminating Stock Option Problems Illumina's stock options are getting a little ridiculous. This problem was pointed out in the third quarter last year, and it doesn't seem to be going away.
Bio-IT World November 14, 2003 Julia Boguslavsky	Genome Center in a Box Scientists at 454 Life Sciences developed an integrated end-to-end instrument that performs hundreds of thousands of reactions in parallel -- from sample preparation, amplification, and sequencing to data storage and bioinformatics.
IEEE Spectrum March 2013 Susan Hassler	Genome to Go It's already possible to have your own genome sequenced. But personalized medicine based on sequencing still has a way to go
The Motley Fool May 2, 2006 Stephen D. Simpson	Still Fishing for Value at Fisher At the right price, this would be an interesting play on health care and biomedical research. Investors, take note.
The Motley Fool August 6, 2008 Brian Orelli	Illumina Grabs Some Cash With biochip maker Illumina hitting 52-week highs, it seems inevitable that the company would do a secondary offering to grab some cash -- about $300 million, as it turns out.
The Motley Fool October 27, 2010 Ralph Casale	Companion Diagnostics in Cancer Drug Development Diagnostic companies partnering with drug developers can make for an attractive investment segment.
Chemistry World January 28, 2015 Rebecca Trager	Roche chases bolt-on acquisitions as it pushes into genomics A recent spending spree by Roche is intended to take advantage of emerging molecular information and genomic analysis, as the company anticipates that the field will play an increasingly important role for future medicines and diagnostics.
HHMI Bulletin May 2012 Sarah C. P. Williams	Opening the Floodgates Researchers are using exome sequencing -- zeroing in on the genes that encode proteins -- to explore the biology of certain diseases.